<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">hJs5YSwSGsj8wtXRW6ZhBLL</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2025000600207</article-id>
      <article-id pub-id-type="other">00207</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20250361</article-id>
      <article-id pub-id-type="publisher-id">abc.20250361</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Minieditorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evid&#234;ncias Brasileiras Refor&#231;am a Aplicabilidade dos Escores H2FPEF e HFA-PEFF na ICFEp</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-7427-3237</contrib-id>
          <name>
            <surname>Farsky</surname>
            <given-names>Pedro Silvio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1">
          <label>1</label>
          <institution content-type="orgname">Instituto Dante Pazzanese de Cardiologia</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
        <aff id="aff2">
          <label>2</label>
          <institution content-type="orgname">Hospital Israelita Albert Einstein</institution>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brasil</country>
          <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP &#8211; Brasil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1"><label>Correspond&#234;ncia:</label><bold>Pedro Silvio Farsky &#8226;</bold> Instituto Dante Pazzanese de Cardiologia &#8211; Av. Dante Pazzanese, 500. CEP <postal-code>04012180</postal-code>, S&#227;o Paulo, SP &#8211; Brasil E-mail: <email>pedro.farsky@gmail.com</email> </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>29</day>
        <month>08</month>
        <year>2025</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <year>2025</year>
      </pub-date>
      <volume>122</volume>
      <issue>06</issue>
      <elocation-id>e20250361</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>05</month>
          <year>2025</year>
        </date>
        <date date-type="rev-recd">
          <day>21</day>
          <month>05</month>
          <year>2025</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>05</month>
          <year>2025</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License</license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <title>Palavras-chave</title>
        <kwd>Medi&#231;&#227;o de Risco</kwd>
        <kwd>Progn&#243;stico</kwd>
        <kwd>Insufici&#234;ncia Card&#237;aca Diast&#243;lica</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>A insufici&#234;ncia card&#237;aca com fra&#231;&#227;o de eje&#231;&#227;o preservada (ICFEp) continua sendo um desafio diagn&#243;stico na cardiologia moderna. Representando aproximadamente metade de todos os casos de insufici&#234;ncia card&#237;aca, essa condi&#231;&#227;o apresenta fisiopatologia complexa, crit&#233;rios diagn&#243;sticos frequentemente subjetivos e op&#231;&#245;es terap&#234;uticas mais limitadas.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup> Nesse contexto, o uso de sistemas de pontua&#231;&#227;o diagn&#243;stica, como H2FPEF e HFA-PEFF, ganhou import&#226;ncia, fornecendo aos m&#233;dicos ferramentas padronizadas e baseadas em evid&#234;ncias para orientar tanto o diagn&#243;stico quanto a estratifica&#231;&#227;o de risco.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup></p>
    <p>Um estudo prospectivo realizado em um hospital terci&#225;rio brasileiro fornece dados relevantes sobre a aplicabilidade desses escores em nossa popula&#231;&#227;o.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Realizado entre mar&#231;o de 2019 e dezembro de 2021, o estudo incluiu 103 pacientes com diagn&#243;stico de ICFEp, acompanhados por aproximadamente 2,4 anos. Al&#233;m da caracteriza&#231;&#227;o cl&#237;nica e ecocardiogr&#225;fica, todos os pacientes foram submetidos a teste de esfor&#231;o, e os escores H2FPEF e HFA-PEFF foram calculados. Os pacientes foram ent&#227;o categorizados em grupos de probabilidade intermedi&#225;ria e alta, de acordo com os pontos obtidos, e acompanhados para o desfecho composto de mortalidade por todas as causas e hospitaliza&#231;&#245;es por insufici&#234;ncia card&#237;aca.</p>
    <p>Os resultados s&#227;o estimulantes e t&#234;m implica&#231;&#245;es cl&#237;nicas pr&#225;ticas. O escore H2FPEF demonstrou melhor desempenho na previs&#227;o de desfechos adversos, com uma &#225;rea sob a curva ROC (<italic>Receiver Operating Characteristic</italic>) de 0,637 (p = 0,035). Em contraste, o escore HFA-PEFF apresentou uma AUC de 0,572, sem signific&#226;ncia estat&#237;stica (p = 0,270).<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Al&#233;m disso, a an&#225;lise de Kaplan-Meier revelou que pacientes com alta probabilidade de ICFEp, de acordo com ambas as pontua&#231;&#245;es, tiveram significativamente mais eventos cardiovasculares quando comparados &#224;queles com pontua&#231;&#245;es intermedi&#225;rias ou discordantes.</p>
    <p>Esses achados oferecem tr&#234;s contribui&#231;&#245;es importantes para a pr&#225;tica cardiol&#243;gica brasileira.</p>
    <p>Em primeiro lugar, refor&#231;am a utilidade progn&#243;stica dos escores H2FPEF e HFA-PEFF. Embora ambos tenham sido desenvolvidos principalmente para fins diagn&#243;sticos &#8212; H2FPEF nos Estados Unidos, com base em vari&#225;veis cl&#237;nicas simples como IMC, idade, fibrila&#231;&#227;o atrial, hipertens&#227;o, press&#227;o pulmonar e volume atrial esquerdo;<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> e HFA-PEFF pela Sociedade Europeia de Cardiologia, com uma abordagem mais estruturada e gradual, incluindo ecocardiografia, biomarcadores e testes funcionais &#8212; ambos demonstraram, em v&#225;rios estudos internacionais, uma associa&#231;&#227;o com resultados cl&#237;nicos.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Este estudo brasileiro confirma que tal associa&#231;&#227;o tamb&#233;m &#233; v&#225;lida em nossa popula&#231;&#227;o, historicamente sub-representada na literatura internacional.</p>
    <p>Em segundo lugar, os resultados sugerem que o escore H2FPEF pode ser uma ferramenta mais sens&#237;vel para estratifica&#231;&#227;o de risco em pacientes com ICFEp. Sua simplicidade, baseada em vari&#225;veis cl&#237;nicas facilmente obtidas em ambientes ambulatoriais, o torna particularmente atraente no contexto brasileiro, onde o acesso a testes diagn&#243;sticos mais complexos pode ser limitado.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Embora a pontua&#231;&#227;o HFA-PEFF ofere&#231;a robustez metodol&#243;gica, sua aplica&#231;&#227;o completa muitas vezes requer infraestrutura de diagn&#243;stico que n&#227;o est&#225; dispon&#237;vel fora dos principais centros.</p>
    <p>Em terceiro lugar, a observa&#231;&#227;o de que pacientes com alta probabilidade de acordo com ambas as pontua&#231;&#245;es apresentaram mais eventos, enquanto aqueles com pontua&#231;&#245;es intermedi&#225;rias ou discordantes tiveram um curso mais favor&#225;vel, levanta a possibilidade de uma estrat&#233;gia combinada no uso do escore. Em outras palavras, o uso de ambas as ferramentas de forma complementar para identificar pacientes cujo risco &#233; consistente em ambos os modelos e, portanto, pode justificar um monitoramento mais rigoroso e potencial intensifica&#231;&#227;o terap&#234;utica.</p>
    <p>No entanto, o estudo apresenta algumas limita&#231;&#245;es que devem ser consideradas. O tamanho relativamente pequeno da amostra e o fato de ter sido conduzido em um &#250;nico centro limitam a generaliza&#231;&#227;o dos resultados. Al&#233;m disso, o n&#250;mero de eventos foi modesto, o que pode ter impactado a precis&#227;o estat&#237;stica, particularmente para o escore HFA-PEFF. No entanto, esses dados lan&#231;am luz sobre um t&#243;pico cl&#237;nico altamente relevante e destacam a necessidade de estudos multic&#234;ntricos maiores no Brasil.</p>
    <p>No contexto da pr&#225;tica cl&#237;nica, este estudo fornece subs&#237;dios para a incorpora&#231;&#227;o do escore H2FPEF como uma ferramenta &#250;til tanto para diagn&#243;stico quanto para progn&#243;stico em pacientes com insufici&#234;ncia card&#237;aca suspeita ou confirmada com fra&#231;&#227;o de eje&#231;&#227;o preservada (ICFEp). Seu uso pode auxiliar nos processos de tomada de decis&#227;o, como a necessidade de investiga&#231;&#227;o adicional, escalonamento terap&#234;utico ou acompanhamento mais pr&#243;ximo. Embora o escore HFA-PEFF n&#227;o tenha demonstrado superioridade progn&#243;stica nesta coorte, ele permanece valioso como uma abordagem estruturada, particularmente em ambientes acad&#234;micos ou quando a incerteza diagn&#243;stica persiste ap&#243;s a avalia&#231;&#227;o inicial.<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
    <p>Por fim, &#233; essencial enfatizar a import&#226;ncia deste estudo para o fornecimento de evid&#234;ncias nacionais em um campo tradicionalmente dominado por dados internacionais. A ICFEp &#233; uma condi&#231;&#227;o prevalente, impactante e desafiadora. Escores como H2FPEF e HFA-PEFF n&#227;o substituem o julgamento cl&#237;nico, mas s&#227;o aliados valiosos como ferramentas diagn&#243;sticas, auxiliando no processo de estratifica&#231;&#227;o de risco. &#192; medida que avan&#231;amos em dire&#231;&#227;o a uma medicina cada vez mais personalizada, baseada em evid&#234;ncias e sens&#237;vel ao contexto local, estudos como este s&#227;o essenciais para orientar a tomada de decis&#245;es &#224; beira do leito.</p>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>Minieditorial referente ao artigo:</label>
        <p>Aplica&#231;&#245;es Progn&#243;sticas dos Escores Cl&#237;nicos Atuais em Insufici&#234;ncia Card&#237;aca com Fra&#231;&#227;o de Eje&#231;&#227;o Preservada: Um Estudo de Coorte Prospectivo</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Borlaug</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Heart Failure with Preserved Ejection Fraction: A Review</article-title>
          <source>JAMA</source>
          <year>2023</year>
          <volume>329</volume>
          <issue>10</issue>
          <fpage>827</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2023.2020</pub-id>
        </element-citation>
        <mixed-citation>1 Redfield MM, Borlaug BA. Heart Failure with Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827-38. doi: 10.1001/jama.2023.2020.</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reddy</surname>
              <given-names>YNV</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Obokata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Borlaug</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction</article-title>
          <source>Circulation</source>
          <year>2018</year>
          <volume>138</volume>
          <issue>9</issue>
          <fpage>861</fpage>
          <lpage>870</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034646</pub-id>
        </element-citation>
        <mixed-citation>2 Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. Circulation. 2018;138(9):861-70. doi: 10.1161/CIRCULATIONAHA.118.034646.</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pieske</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tsch&#246;pe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>de Boer</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Donal</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA-PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)</article-title>
          <source>Eur J Heart Fail</source>
          <year>2020</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>391</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="doi">10.1002/ejhf.1741</pub-id>
        </element-citation>
        <mixed-citation>3 Pieske B, Tsch&#246;pe C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA-PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(3):391-412. doi: 10.1002/ejhf.1741.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barros</surname>
              <given-names>FC</given-names>
            </name>
            <name>
              <surname>Cezaro</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>ABS</given-names>
            </name>
            <name>
              <surname>Pianca</surname>
              <given-names>EG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic Applications of Current Clinical Scores in Heart Failure with Preserved Ejection Fraction: A Prospective Cohort Study</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2025</year>
          <volume>122</volume>
          <issue>6</issue>
          <elocation-id>e20240852</elocation-id>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240852">https://doi.org/10.36660/abc.20240852</ext-link>
          </comment>
        </element-citation>
        <mixed-citation>4 Barros FC, Cezaro JC, Costa PD, Costa GD, Santos ABS, Pianca EG, et al. Prognostic Applications of Current Clinical Scores in Heart Failure with Preserved Ejection Fraction: A Prospective Cohort Study. Arq Bras Cardiol. 2025; 122(6):e20240852. DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20240852">https://doi.org/10.36660/abc.20240852</ext-link>.</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Myhre</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Vaduganathan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Claggett</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>CSP</given-names>
            </name>
            <name>
              <surname>Desai</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Anand</surname>
              <given-names>IS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Application of the H2 FPEF Score to a Global Clinical Trial of Patients with Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial</article-title>
          <source>Eur J Heart Fail</source>
          <year>2019</year>
          <volume>21</volume>
          <issue>10</issue>
          <fpage>1288</fpage>
          <lpage>1291</lpage>
          <pub-id pub-id-type="doi">10.1002/ejhf.1542</pub-id>
        </element-citation>
        <mixed-citation>5 Myhre PL, Vaduganathan M, Claggett BL, Lam CSP, Desai AS, Anand IS, et al. Application of the H2 FPEF Score to a Global Clinical Trial of Patients with Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial. Eur J Heart Fail. 2019;21(10):1288-91. doi: 10.1002/ejhf.1542.</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obokata</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>YNV</given-names>
            </name>
            <name>
              <surname>Borlaug</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods</article-title>
          <source>JACC Cardiovasc Imaging</source>
          <year>2020</year>
          <volume>13</volume>
          <issue>1 Pt 2</issue>
          <fpage>245</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jcmg.2018.12.034</pub-id>
        </element-citation>
        <mixed-citation>6 Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):245-57. doi: 10.1016/j.jcmg.2018.12.034.</mixed-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="S1" xml:lang="en">
    <front-stub>
      <article-id pub-id-type="doi">10.36660/abc.20250361i</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Editorial</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Brazilian Evidence Reinforces the Applicability of the H2FPEF and HFA-PEFF Scores in HFpEF</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0001-7427-3237</contrib-id>
          <name>
            <surname>Farsky</surname>
            <given-names>Pedro Silvio</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="c2"/>
        </contrib>
        <aff id="aff3">
          <label>1</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Instituto Dante Pazzanese de Cardiologia, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
        <aff id="aff4">
          <label>2</label>
          <addr-line>
            <named-content content-type="city">S&#227;o Paulo</named-content>
            <named-content content-type="state">SP</named-content>
          </addr-line>
          <country country="BR">Brazil</country>
          <institution content-type="original">Hospital Israelita Albert Einstein, S&#227;o Paulo, SP &#8211; Brazil</institution>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c2"><label>Mailing Address:</label><bold>Pedro Silvio Farsky &#8226;</bold> Instituto Dante Pazzanese de Cardiologia &#8211; Av. Dante Pazzanese, 500. Postal Code <postal-code>04012180</postal-code>, S&#227;o Paulo, SP &#8211; Brazil E-mail: <email>pedro.farsky@gmail.com</email> </corresp>
      </author-notes>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Risk Assessment</kwd>
        <kwd>Prognosis</kwd>
        <kwd>Diastolic Heart Failure</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>Heart failure with preserved ejection fraction (HFpEF) remains a diagnostic challenge in modern cardiology. Representing approximately half of all heart failure cases, this condition presents with complex pathophysiology, often subjective diagnostic criteria, and more limited therapeutic options.<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup> In this context, the use of diagnostic scoring systems, such as H2FPEF and HFA-PEFF, has gained importance, providing clinicians with standardized and evidence-based tools to guide both diagnosis and risk stratification.<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>A prospective study conducted at a Brazilian tertiary hospital provides relevant data on the applicability of these scores in our population.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Conducted between March 2019 and December 2021, the study included 103 patients diagnosed with HFpEF, who were followed for approximately 2.4 years. In addition to clinical and echocardiographic characterization, all patients underwent exercise testing, and both the H2FPEF and HFA-PEFF scores were calculated. Patients were then categorized into intermediate- and high-probability groups according to the score points obtained and followed for the composite outcome of all-cause mortality and heart failure hospitalizations.</p>
      <p>The results are stimulating and have practical clinical implications. The H2FPEF score demonstrated better performance in predicting adverse outcomes, with an area under the receiver operating characteristic curve (AUC) of 0.637 (p = 0.035). In contrast, the HFA-PEFF score presented an AUC of 0.572 without statistical significance (p = 0.270).<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Moreover, Kaplan-Meier analysis revealed that patients with a high probability of HFpEF, according to both scores, had significantly more cardiovascular events when compared to those with intermediate or discordant scores.</p>
      <p>These findings offer three important contributions to Brazilian cardiology practice.</p>
      <p>First, they reinforce the prognostic utility of the H2FPEF and HFA-PEFF scores. Although both were developed primarily for diagnostic purposes &#8212; H2FPEF in the United States, based on simple clinical variables such as BMI, age, atrial fibrillation, hypertension, pulmonary pressure, and left atrial volume;<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref></sup> and HFA-PEFF by the European Society of Cardiology, with a more structured and stepwise approach including echocardiography, biomarkers, and functional testing &#8212; both have shown, in various international studies, an association with clinical outcomes.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> This Brazilian study confirms that such an association is also valid in our population, which has historically been underrepresented in the international literature.</p>
      <p>Second, the results suggest that the H2FPEF score may be a more sensitive tool for risk stratification in patients with HFpEF. Its simplicity, based on easily obtainable clinical variables in outpatient settings, makes it particularly attractive in the Brazilian context, where access to more complex diagnostic tests may be limited.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Although the HFA-PEFF score offers methodological robustness, its full application often requires diagnostic infrastructure that is unavailable outside major centers.</p>
      <p>Third, the observation that patients with a high probability according to both scores experienced more events, while those with intermediate or discordant scores had a more favorable course, raises the possibility of a combined strategy in score usage. In other words, using both tools in a complementary fashion to identify patients whose risk is consistent across both models and, therefore, may warrant closer monitoring and potential therapeutic intensification.</p>
      <p>However, the study has some limitations that must be considered. The relatively small sample size and the fact that it was conducted in a single center limit the generalizability of the results. Additionally, the number of events was modest, which may have impacted statistical accuracy, particularly for the HFA-PEFF score. Nonetheless, these data shed light on a highly relevant clinical topic and highlight the need for larger multicenter studies in Brazil.</p>
      <p>In the context of clinical practice, this study provides support for incorporating the H2FPEF score as a useful tool for both diagnosis and prognosis in patients with suspected or confirmed heart failure with preserved ejection fraction (HFpEF). Its use may assist in decision-making processes, such as the need for further investigation, therapeutic escalation, or closer follow-up. Although the HFA-PEFF score did not demonstrate prognostic superiority in this cohort, it remains valuable as a structured approach, particularly in academic settings or when diagnostic uncertainty persists after the initial evaluation.<sup><xref ref-type="bibr" rid="B6">6</xref></sup></p>
      <p>Finally, it is essential to emphasize the significance of this study in providing national evidence in a field traditionally dominated by international data. HFpEF is a prevalent, impactful, and challenging condition. Scores such as H2FPEF and HFA-PEFF do not replace clinical judgment, but they are valuable allies as diagnostic tools, aiding in the risk stratification process. As we move toward increasingly personalized, evidence-based medicine that is sensitive to the local context, studies like this are essential for guiding bedside decision-making.</p>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other" id="fn2">
          <label>Short Editorial related to the article:</label>
          <p>Prognostic Applications of Current Clinical Scores in Heart Failure with Preserved Ejection Fraction: A Prospective Cohort Study</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
